KD Pharma Group Refinances €150 Million Debt Facilities

19 June 2019

The KD Pharma Group has rearranged and expanded its debt facilities, raising €150 million in total financing through the facilities. The solution includes a term loan to refinance existing debt, a capex facility for production expansion as well as a revolving credit facility and is fully underwritten by Deutsche Bank Direct Lending Europe.


The refinancing is a component of the company’s growth strategy, which has also included the recent acquisition of a new pharmaceutical plant in Seal Sands, United Kingdom. “KD Pharma is undergoing rapid growth and having Deutsche Bank as a partner for the expanded debt facilities will enable KD to build out capacity and continue to grow profitably,” said Igor van Santen, KD Pharma Group’s CFO. 


Herter and Co. acted as the Sole Debt Adviser on the rearrangement and expansion of the debt facilities.


 

 

About the KD Pharma Group SA:

The KD Pharma Group is the third largest Omega-3 producer in the world with 500 people and 6 sites located in the UK, Norway, Germany and the US. The company concentrates nutraceutical and pharmaceutical oils and makes customized finished products for its customers in soft gel capsule and bottled liquid forms. The KD Pharma Group has the global reach, technology and vertical integration necessary to develop customized Omega-3 products with complete supply chain efficiency for our customers.  


Contact:

Adam Ismail
Chief Strategy Officer
KD Pharma Group
+1 (385) 237-2787
adam.ismail@kdpharmagroup.com